Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Enveric Biosciences IncTrade
Hewlett Packard Enterprise CoTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Hewlett Packard Enterprise Co — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Hewlett Packard Enterprise Co trades at $55.2 (market cap $72.41B). The key difference: Hewlett Packard Enterprise Co is far larger — about 11679× Enveric Biosciences Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

ENVBHPE
Market Cap
$6.20M$72.41B
Sector
HealthTechnology
52-Week High
$17.40$56.14
52-Week Low
$1.27$20.01
Enterprise Value
$1.30M$88.36B
Dividend Yield
1.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Hewlett Packard Enterprise Co

HPE stock trades at $53.22, up 1.49% today, near its pivot point of $53, with bullish moving averages but overbought RSI signals. Recent earnings beats, including Q1 2026 EPS of $0.79 versus $0.535 expected, and a Morgan Stanley upgrade on August 10, 2026, highlight AI infrastructure demand strength. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows.

The outlook is positive with a consensus price target of $69.81, implying 31% upside, supported by AI server trends. Risks include volatile cash flows, rising debt-to-asset ratio to 29.48% in 2025, and intense competition. Investors should weigh growth potential against execution risks in a high-valuation environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE